Zalutumumab

DB12202InvestigationalProtein Based Therapies

Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₆₅₁₂H₁₀₀₇₄N₁₇₃₄O₂₀₃₂S₄₆ · 146641.0546 Da
Code names: 2F8

Resolves to

Compound

UNIIDA709Q5020CAS667901-13-5ChEMBLCHEMBL2107861KEGGD10031

Targets

P00533EGFR

What you can answer from here — as of February 21, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

420Drug interactionsStructured to mechanism, not free text

10Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zalutumumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account